Blueprint Medicines, a Cambridge, MA-based developer of personalized cancer therapies, announced Fidelity Biosciences as a new investor.
Fidelity Biosciences has joined existing founding investor Third Rock Ventures in the company’s previously announced $40m Series A financing (read here).
Founded in 2011 by Nicholas Lydon, Ph.D., Brian Druker, M.D., and Third Rock, and led by Chris Varma, Ph.D., president and CEO, Blueprint Medicines uses its Insights-to-Validation™ Platform and proprietary chemical library to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. of Blueprint Medicines.
In conjunction with the funding, Stephen C. Knight, M.D., president and managing partner of Fidelity Biosciences, will join the company’s board of directors, which includes existing members Mark Levin and Alexis Borisy of Third Rock Ventures, Chris Varma, and independent director Nick Lydon, Ph.D.
FinSMEs
24/05/2012